1-20 of 20
Authors: Ana González-Cordón
Journal Article
Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study Get access
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 9, September 2024, Pages 2343–2353, https://doi.org/10.1093/jac/dkae235
Published: 24 July 2024
Journal Article
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis Get access
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 8, August 2024, Pages 1775–1783, https://doi.org/10.1093/jac/dkae138
Published: 17 May 2024
Journal Article
Efficacy and safety of raltegravir plus lamivudine maintenance therapy Free
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 2, February 2024, Pages 255–261, https://doi.org/10.1093/jac/dkad364
Published: 01 December 2023
Journal Article
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting Free
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 12, December 2023, Pages 2961–2967, https://doi.org/10.1093/jac/dkad338
Published: 24 October 2023
Journal Article
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir Free
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 9, September 2023, Pages 2361–2365, https://doi.org/10.1093/jac/dkad247
Published: 04 August 2023
Journal Article
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study Free
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 8, August 2023, Pages 1955–1962, https://doi.org/10.1093/jac/dkad189
Published: 13 June 2023
Journal Article
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study Free
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 7, July 2022, Pages 1974–1979, https://doi.org/10.1093/jac/dkac137
Published: 05 May 2022
Journal Article
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study Free
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 7, July 2022, Pages 1980–1988, https://doi.org/10.1093/jac/dkac117
Published: 13 April 2022
Journal Article
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre Free
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 4, April 2022, Pages 1133–1139, https://doi.org/10.1093/jac/dkab481
Published: 19 January 2022
Journal Article
Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort Free
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 11, November 2021, Pages 2988–2992, https://doi.org/10.1093/jac/dkab261
Published: 22 July 2021
Journal Article
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV Free
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 9, September 2021, Pages 2380–2393, https://doi.org/10.1093/jac/dkab158
Published: 13 June 2021
Journal Article
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease Free
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 11, November 2020, Pages 3334–3343, https://doi.org/10.1093/jac/dkaa292
Published: 31 July 2020
Journal Article
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study Free
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 7, July 2020, Pages 1955–1960, https://doi.org/10.1093/jac/dkaa072
Published: 05 March 2020
Journal Article
Factors associated with the number of drugs in darunavir/cobicistat regimens Free
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 1, January 2020, Pages 208–214, https://doi.org/10.1093/jac/dkz399
Published: 05 October 2019
Journal Article
Tolerability of integrase inhibitors in a real-life setting Free
Journal of Antimicrobial Chemotherapy, Volume 72, Issue 6, June 2017, Pages 1752–1759, https://doi.org/10.1093/jac/dkx053
Published: 28 February 2017
Journal Article
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression Free
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 7, July 2016, Pages 1975–1981, https://doi.org/10.1093/jac/dkw078
Published: 28 March 2016
Journal Article
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection Free
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 7, July 2016, Pages 1982–1986, https://doi.org/10.1093/jac/dkw048
Published: 18 March 2016
Journal Article
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection Free
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 7, July 2016, Pages 1987–1993, https://doi.org/10.1093/jac/dkw049
Published: 18 March 2016
Journal Article
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 4, April 2015, Pages 1130–1138, https://doi.org/10.1093/jac/dku501
Published: 23 December 2014
Journal Article
Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study Get access
Journal of Antimicrobial Chemotherapy, Volume 69, Issue 3, March 2014, Pages 742–748, https://doi.org/10.1093/jac/dkt406
Published: 14 October 2013
